Latest Breaking News On - Sandi greenwood - Page 9 : comparemela.com

Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01

/PRNewswire/ Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and.

United statesEleanor perkinFrazer hallSamson fungMarcin szumowskiAndre hoekemaMagdalena lickaSandi greenwoodWarsaw stock exchangeInternational institute of molecularChief business officerDavid dibleInternational instituteCell biology

Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01

Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesEleanor perkinFrazer hallMarcin szumowskiAndre hoekemaSamson fungKostenloser wertpapierhandelSandi greenwoodMagdalena lickaWarsaw stock exchangeInternational institute of molecularChief business officerDavid dibleInternational instituteCell biology

Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients

/PRNewswire/ Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, today.

Frazer hallUnited statesFlorent grosSylvie berrebiPrnewswire priotheraSandi greenwoodHead of regulatory affairs at priotheraTekla capital managementDrug administrationFast trackHematopoietic stem cell transplantAcute myeloid leukemiaVon graevenitzRegulatory affairsFountain healthcare partnersEarlybird venture capital

Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

- Neumifil is a novel broad-spectrum anti-viral product that was shown to be well-tolerated with no safety signals at all doses tested - Pneumagen plans to conduct a Phase 2 Influenza challenge

United kingdomFrazer hallPrnewswire pneumagenKostenloser wertpapierhandelGeoff kitsonDouglas thomsonEvelyn mccormackSandi greenwoodUniversity of st andrewsChief medical officerRespiratory syncytial virusDavid dibleCarbohydrate binding moleculeInfluenza virus

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

/PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a novel intranasal spray which is designed to provide patients at risk with an.

South africaUnited kingdomCity ofSouth africanJohn beadleFrazer hallPrnewswire pneumagenDouglas thomsonJohn beadleaddedSandi greenwoodLondon business schoolPsioxus therapeutics ltdAfrican college of medicineEntrepreneur in residence at imperial collegeUniversity of st andrewsUniversity of the witwatersrand